A strategy for Cas13 miniaturization based on the structure and AlphaFold

被引:7
|
作者
Zhao, Feiyu [1 ,2 ]
Zhang, Tao [1 ,2 ]
Sun, Xiaodi [1 ,2 ]
Zhang, Xiyun [1 ,2 ]
Chen, Letong [1 ,2 ]
Wang, Hejun [1 ,2 ]
Li, Jinze [1 ,2 ]
Fan, Peng [1 ,2 ]
Lai, Liangxue [1 ,2 ,3 ,4 ]
Sui, Tingting [1 ,2 ]
Li, Zhanjun [1 ,2 ]
机构
[1] Jilin Univ, Minist Educ, Key Lab Zoonosis Res, Inst Zoonosis,State Key Lab Zoonot Dis, Changchun 130062, Peoples R China
[2] Jilin Univ, Coll Vet Med, Changchun 130062, Peoples R China
[3] Jilin Univ, Coll Vet Med, Jilin Prov Key Lab Anim Embryo Engn, Changchun, Peoples R China
[4] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, Guangzhou 510530, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
NUCLEIC-ACID DETECTION; RNA; DISEASE;
D O I
10.1038/s41467-023-41320-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The small size of the Cas nuclease fused with various effector domains enables a broad range of function. Although there are several ways of reducing the size of the Cas nuclease complex, no efficient or generalizable method has been demonstrated to achieve protein miniaturization. In this study, we establish an Interaction, Dynamics and Conservation (IDC) strategy for protein miniaturization and generate five compact variants of Cas13 with full RNA binding and cleavage activity comparable the wild-type enzymes based on a combination of IDC strategy and AlphaFold2. In addition, we construct an RNA base editor, mini-Vx, and a single AAV (adeno-associated virus) carrying a mini-RfxCas13d and crRNA expression cassette, which individually shows efficient conversion rate and RNA-knockdown activity. In summary, these findings highlight a feasible strategy for generating downsized CRISPR/Cas13 systems based on structure predicted by AlphaFold2, enabling targeted degradation of RNAs and RNA editing for basic research and therapeutic applications. Small Cas enzymes are required for therapeutic use. Here the authors report an Interaction, Dynamics and Conservation (IDC) strategy for protein miniaturisation and use this to generate five compact variants of Cas13 based on a combination of IDC strategy and AlphaFold2.
引用
下载
收藏
页数:13
相关论文
共 50 条
  • [21] Engineered Cas13 variants with minimal collateral RNA targeting
    Nature Biotechnology, 2023, 41 : 29 - 30
  • [22] Programmable Inhibition and Detection of RNA Viruses Using Cas13
    Freije, Catherine A.
    Myhrvold, Cameron
    Boehm, Chloe K.
    Lin, Aaron E.
    Welch, Nicole L.
    Carter, Amber
    Metsky, Hayden C.
    Luo, Cynthia Y.
    Abudayyeh, Omar O.
    Gootenberg, Jonathan S.
    Yozwiak, Nathan L.
    Zhang, Feng
    Sabeti, Pardis C.
    MOLECULAR CELL, 2019, 76 (05) : 826 - +
  • [23] CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9
    Yan, Fancheng
    Wang, William
    Zhang, Jiaqiang
    CELL BIOLOGY AND TOXICOLOGY, 2019, 35 (06) : 489 - 492
  • [24] Transforming plant biology and breeding with CRISPR/Cas9, Cas12 and Cas13
    Schindele, Patrick
    Wolter, Felix
    Puchta, Holger
    FEBS LETTERS, 2018, 592 (12) : 1954 - 1967
  • [25] Commentary - CRISPR-based techniques: Cas9, Cas13 and their applications in the era of COVID-19
    Zaami, S.
    Piergentili, R.
    Marinelli, E.
    Vergallo, G. Montanari
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (03) : 1752 - 1761
  • [26] Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms
    Tian, Songhai
    Liu, Yang
    Appleton, Evan
    Wang, Huan
    Church, George M.
    Dong, Min
    CELL REPORTS, 2022, 38 (10):
  • [27] Intrinsic targeting of host RNA by Cas13 constrains its utility
    Li, Zexu
    Li, Zihan
    Cheng, Xiaolong
    Wang, Shengnan
    Wang, Xiaofeng
    Ma, Shixin
    Lu, Zhiyan
    Zhang, Han
    Zhao, Wenchang
    Chen, Zhisong
    Yao, Yingjia
    Zhang, Cheng
    Chao, Lumen
    Li, Wei
    Fei, Teng
    NATURE BIOMEDICAL ENGINEERING, 2024, 8 (02) : 177 - +
  • [28] CRISPR/Cas13: A potential therapeutic option of COVID-19
    Lotfi, Melika
    Rezaei, Nima
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 131
  • [29] Transient and lentiviral delivery of CRISPR/Cas13 system to knockdown oncogenes
    Puig-Serra, P.
    Martinez-Lage, M.
    Casado-Rosas, M. C.
    Olalla-Sastre, B.
    Torres-Ruiz, R.
    Rodriguez-Perales, S.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A77 - A77
  • [30] Streamlined detection of SARS-CoV-2 via Cas13
    Ahmed Ghouneimy
    Magdy Mahfouz
    Nature Biomedical Engineering, 2022, 6 : 925 - 927